英語BP辯論反方一辯辯論稿

英語BP辯論反方一辯辯論稿英語BP辯論反方一辯辯論稿英語BP辯論反方一辯辯論稿xxx公司英語BP辯論反方一辯辯論稿文件編號：文件日期：修訂次數(shù)：第1.0次更改批準(zhǔn)審核制定方案設(shè)計(jì)，管理制度反方一辯：Respectedjudicators,Ladiesandgentlemen,goodevening!Inthefirstpartofmyspeech,Iwouldliketomakemyrebuttal.Patentsdonotcostslives,theysavemore.Ourgovernmentsidehaveproposedaradicalsolutiontotheirproblem:theywanttoignoreintellectualproperty,oneofourmostimportantconstructstoencourageinnovation.Ontheopposition,webelievethestatusquoofallowingamedicinecompanytopatentsomethingandprofitfromitisnecessaryforthemtohaveanincentiveandabilitytocreatelife-savingmedicinesnowandinthefuture,anditissavinglivesinthelong-termthatconcernsus.NowI’dliketoprovidemystatements.Thishousewouldnotabolishpatentsforlife-savingmedicines.Forthefirstreason,ittakesawaytheIncentivetoProduceLife-savingmedicines.RonPollacksaid,Thepharmaceuticalindustry'srepetitiouscrythatresearchanddevelopmentwouldbecurtailedifmedicinepricesaremoderatedisextraordinarilymisleading.Yes,researchanddevelopmentcostsmoney.Yetonly14%ofpharmaceuticals'budgetsgotoresearchanddevelopment.Reportshavelinked"highmedicinepricestoadvertising,profitsandenormousexecutivesalaries.Thereportdocumentsthatmedicinecompaniesarespendingmorethantwiceasmuchonmarketing,advertising,andadministration.”Firmsareincentivizedtoundertakeresearchinlife-savingdrugsbecausenowtheyhaveaguaranteedreturnontheirR&Dinvestment.Regardlessofthecourseofdrugproductionanddistributiontheywillbeprofitfromtheirresearch.Inaddition,Scientistsareprincipallymotivatedbythedesireforpeerrecognitionandalsobythefactthattheywanttohaveachievedsomethingmorewiththeirlivesthanreducesometeenager’spimplesby30%.Wearenotdissuadingresearchintolive-savingillnesseswe’reinvigoratingitbyofferingincitingprofitthatistiedtoresultsandiscost-effective.Creatingabrandnewmedicinerequiresenormousamountsofmoneyandfailedattempts,andthereforeinvolvesalargeamountofrisk.Ifapersoncan'tbeguaranteedsomekindofcontrolorreturntothatriskandexpense,theyareunlikelytowanttoinvestinit.Inparticular,ifamedicinecompanycanmakemoremoneybypatentingmedicinesthatcurehairloss,theywilltakethatoption.Forthesecondaspect,consequencesofthelossofincentivesisawful.Medicinecompaniesaretryingtodevelopcuresforcancer,diabetesandmore,andwilllikelywanttodevelopmorecuresforillnessesthatcomeupinthefuture,astheydidforswineflu,iftheycangetareturnontheinvestment.Ifthereisnotasignificantreturntoinvestment,acompanywillnotbothertocontinuetoresearchanddevelopthesemedicines.Evenifthecurrentmedicineswerereleasedforgenericdevelopment,lackoffuturemedicineswouldcostfarmorelivesinthelongrun,andsavemoneyonalternativetreatments.Furthermore,mostthingsthatcauseillness,suchasvirusesandbacteria,developsothattheycanresistmedicines.Wehaveseenthisinthecaseoftheincreasedineffectivenessofantibiotics.Propwantstochangethefocusofmedicineproductionfromthedevelopmentofnewmedicinestothecheaperproductionofmedicinesthatalreadyexist.Thiswillhappenbecauseanystart-upcompanyorinvestorinthemedicinesindustrywillseethatitischeapertosimplycreatethemedicines,ratherthanputmoneyintoresearchanddevelopment,whichisthemostexpensivepartofthemedicinescreationprocess.Ifthereisagreaterfocusonthis,thenlessnewmedicineswillbecreatedtocombattheillnesses.Thisstructurebeginstolookveryflawedastheillnessesdevelopresistancestooldmedicines.Thereneedstobeacontinuingincentivetocreatenewmedicinesforanyillness,nottosimplyfocusonoldmedicinesbeingcreatedinlarger,cheaperamounts.Itisworthslightlymoreexpensivemedicinesifnewinnovationisconstantlyabletohappen.Inconclusion,ifwe